Smack dab in the center of basketball's 3-point golden age, UP star Gerry Abadiano showcases his mid-range mastery as the Fighting Maroons keep their UAAP men'sSmack dab in the center of basketball's 3-point golden age, UP star Gerry Abadiano showcases his mid-range mastery as the Fighting Maroons keep their UAAP men's

Norm-defying Abadiano embraces mid-range shots as UP forces UAAP finals Game 3

2025/12/14 20:50
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

MANILA, Philippines – In this day and age of prolific three-pointers in modern basketball, Gerry Abadiano stubbornly went against the flow.

A graduating star of the UP men’s basketball team, the calm and collected veteran gunner utilized the mid-range shot to incredible effect as the Fighting Maroons pulled off a UAAP Season 88 finals Game 2 escape of rival La Salle, 66-63, on Sunday, December 14, to force a winner-take-all Game 3.

Abadiano torched the nets for 17 points, 6 coming off contested mid-rangers in the final 2:31 of regulation, and did enough damage to help UP force a decider on Wednesday, December 17, at the Araneta Coliseum.

Already a mid-range sniper since his title-winning high school days with the NU Bullpups, the 24-year-old standout said his confidence simply comes from experience from years of UAAP playoff games.

“I didn’t really expect my game to go that way today, but we really just played as a team and attacked the holes in the defense. We were really just hungrier in Game 2 since we lost Game 1,” Abadiano said in Filipino.

“It’s also our last year and personally, I don’t want my last [game] to go like I didn’t do my best.”

For UP assistant coach Christian Luanzon, the Maroons simply played with “desperation” as expected of teams trailing in any finals series, and he now expects his players to leave it all on the line as a heated Game 3 beckons.

“From a personal standpoint, it’s every player’s dream. How many players could wake up and say they’ll play in the UAAP, and then play at a high level?” he said.

“I’m sure, whether a veteran like Gerry in his fifth season or Francis [Nnoruka] in his rookie season, they’d be lying if they say they’re not nervous. At the same time, there’s an excitement there since this is your dream since childhood. In Game 3, I’m sure everything will be summed up into those [clutch] plays.”

For UP, a win on Wednesday means a third championship in five seasons, title No. 4 overall, and more importantly, its first-ever successful title defense in school history, even dating back to its inaugural title run in the 1939-40 season.

Come Wednesday, UP will have one final shot at gold, and fans can certainly count on Abadiano to patrol the mid-range one final time, scouting for his next open looks as if it were just practice time in Diliman. – Rappler.com

Market Opportunity
SQUID MEME Logo
SQUID MEME Price(GAME)
$33.5666
$33.5666$33.5666
+0.52%
USD
SQUID MEME (GAME) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09